Reporter brief
Pilot RCT of metformin-containing combination therapies on healthspan outcomes over 90 days
What happened
This was a 90-day randomized controlled pilot trial comparing three arms: control, multi-therapy (including metformin, naltrexone, B12, and NAD+), and comprehensive therapy (including metformin, rapamycin, naltrexone, B12, NAD+, GSH, and other supplements). The study enrolled up to 30 subjects (approximately 10 per arm) to assess effects on longevity-related outcomes. Effect sizes were not reported.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Small sample size pilot study; specific population characteristics not reported
- Design
- Rct
- Sample
- 30
- Journal
- AgelessRx
- Published
- Mar 16, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.